Efficacy of weekly administration of paclitaxel for advanced or recurrent gastric cancer with peritoneal dissemination
Hikino, H.; Yamada, T.; Hata, T.; Nakamura, K.; Sugimoto, S.; Kanazawa, A.; Tokuka, A.; Ozaki, N.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 31(5): 759-761
2004
ISSN/ISBN: 0385-0684 PMID: 15170988 Document Number: 566930
We report 3 gastric cancer patients with peritoneal dissemination who failed to take TS-1 due to adverse effects and who were successfully treated with weekly paclitaxel administered intravenously. The patients were 2 men and 1 woman from 73 to 82 years in age. The histological types of gastric cancer were undifferentiated adenocarcinoma in all cases. Intravenous infusion of TXL (62-80 mg/m2) after short premedication was continued for 3 weeks followed by 1 week rest. Clinical symptoms, including ascites and intestinal obstruction, improved only after administration of 1 cycle in all patients. Except for 1 event with grade 3 neutropenia, no major adverse reactions were observed. Weekly administration of paclitaxel may be a promising chemotherapy for controlling peritoneal metastasis and improving the quality of life of patients with advanced or recurrent gastric cancer.